"Biopharmaceuticals have universal importance as effective therapeutics for many human diseases. Biopharmaceutical production employs living cells as ‘production machinery’ with the selection of the producing cell line, a critical step for an efficient industrial process. Current industry practices for cell selection are expensive and time-consuming. The proposed PM-CELL project will result in the development of a rapid cellular characterisation testing technology. The two-year project will result in an innovative 96-well micro-titre plate containing a unique array of analytes, which can be used to accelerate development and reduce manufacturing costs of biopharmaceuticals synthesised by mammalian cell lines. A successful project would result in cost savings for the SMEs’ customers in the bioprocessing industry and a more rapid translation of research to efficient drug production for human healthcare. The project would result in generation of a high value (economic and intellectual property) technology which would result in increased sales and assets to the SMEs. The SMES will then be well placed to take advantage of further development opportunities in the biopharmaceutical industry, which is actively looking for innovative solutions for manufacturing-cell selection in drug production."